Peter Hamilton (Moderator)
Chief of Staff & European Director, Paige
1st Dec 2021
Date: 1 December 2021
Time: New York – 12:25 | London – 17:25 | Paris – 18:25 |
Duration: 60 minutes
Event structure: Panel Discussion + Q&A
Registration fee: Complimentary access
Expert Panel Discussion: Paige Receives Clinical Approval for AI In Pathology – What this Means & Will This Accelerate the Digitization of Anatomic Pathology?
The US Food and Drug Administration has granted FDA market authorization to Paige Prostate, a clinical-grade AI solution for prostate cancer detection. This ground-breaking approval means that Paige Prostate is the first and only AI-based pathology product to receive market authorization for in vitro diagnostic (IVD) use. This FDA approval marks the beginning of a new era of clinical care where pathologists will be able to leverage computational pathology products like Paige Prostate to enhance their ability to make a diagnoses and lead to improved patient outcomes.
In this panel session, we will discuss what this news means for the field of pathology and if it will be the catalyst toward a digital transformation in pathology.
AI and Digital Pathology in Clinical Practice: What’s in it for Pathologists?
In this workshop, we will explain what a digital and computational pathology lab looks like and how this can be implement in a real-life clinical setting. The process of digital transformation of the pathology lab, and the benefits and limitations of the use of AI in clinical practice will be discussed. Real life experiences with the use of the technology will be shared in an interactive format that will provide the participants with practical, hands-on information on how to implement digital and AI in their pathology labs